MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$3.92
-0.03 (-0.76%)
▼
5d:
-0.51%
30d:
-18.67%
90d:
-42.1%
BUY
HIGH Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 29, 2026
25d
Smart Money Accumulation
MDXG is down 3.3% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 464 OI. Call ratio: 98% View Scanner →
Strength: 6.5/10
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MDXG appears deeply undervalued. Market expects -18.7% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: MDXG appears deeply undervalued. Market expects -18.7% annual earnings decline despite 100% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.54
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$7.78
49.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $3.92, which is considered oversold relative to its 30-day fair value range of $4.01 to $4.89. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.2) compared to its historical average (28.3). Remarkably, the market is currently pricing in an annual earnings decline of 18.7% over the next few years. This pessimistic expectation contrasts with the company's recent 99.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, MDXG is in a strong downtrend. Immediate support is located at $3.77, while resistance sits at $4.32.
Market Sentiment: MDXG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.67 (+146.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDXG is in a strong downtrend. Immediate support is located at $3.77, while resistance sits at $4.32.
Market Sentiment: MDXG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.67 (+146.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.01 -
$4.89
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 146.6% below Wall St target ($9.67)
Fair Price Analysis
30-Day Fair Range
$4.01 -
$4.89
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.77
Resistance Level
$4.32
Current Trend
Strong Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.22
Wall Street Target
$9.67
(+146.6%)
Revenue Growth (YoY)
27.1%
Earnings Growth (YoY)
99.5%
Profit Margin
11.6%
Valuation Discount vs History
-18.7% cheaper
PE vs Historical
15.2 vs 28.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.7%
(market-implied from PE analysis)
1-Year Target
$3.53
(-10%)
2-Year Target
$3.18
(-19%)
3-Year Target
$2.86
(-27%)
3-Yr Target (if PE normalizes)
(PE: 15→28)
$5.31
(+36%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 98.1%)
$17.88
(+356%)
Base:
(SPY PE: 15.2, Growth: 98.1%)
$13.23
(+238%)
Bear:
(PE: 12.9, Growth: 98.1%)
$11.25
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 12.88 | Current EPS (TTM): $0.32
Bull Case
$3.65
(-14%)
Analyst growth -19.5%, PE expands to 14.2
Base Case
$3.32
(-22%)
Market implied -19.5%, PE stable at 12.9
Bear Case
$2.80
(-34%)
Severe decline -20.0%, PE contracts to 10.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.2 to 28.3
Stabilization Target:
$7.29
(+85.9%)
PE Expansion Potential:
+85.9%
Share & Embed Analysis
Last updated: April 03, 2026 2:25 AM ET
Data refreshes hourly during market hours. Next update: 3:25 AM
Data refreshes hourly during market hours. Next update: 3:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kimberly Maersk-Moller
SELL
58300 shares
2025-11-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$50 | 54 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 52 HOLD |
